May 7, 2011 -- BeiGene, a Beijing oncology startup, announced an initial investment from Merck of unspecified amount, though BeiGene’s CEO described it as “large” in an exclusive interview; Pfizer will purchase a $50 million stake in Shanghai Pharmaceutical’s upcoming Hong Kong IPO; Crown BioScience, a cancer-focused CRO, closed a $28.8 million Series C round; Sinocom Pharma, a drug distributor to third and fourth tier cities, will conduct an IPO on Nasdaq; Steve Yang, head of AstraZeneca’s Asia R&D, discussed the company’s China partnering strategy; C3 Jian of California and Sichuan University will set up a joint clinical research center for diseases of the mouth; and Beijing Second Pharma was granted FDA approval for US use of a long-acting calcium channel blocker. More details….
Stock Symbols: (NYSE: MRK) (NYSE: PFE) (SHA: 601607) (NYSE: AZN)
